Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 70

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 70
---
 may
not have adequate information security measures in place. If our third-party service providers experience a cybersecurity incident or
other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers
fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be
unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that
third parties and infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised or that
they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems,
including our services, or the third-party information technology systems that support us and our services.

Any of the previously identified
or similar threats could cause a cybersecurity incident or other interruption that could result in unauthorized, unlawful, or accidental
acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information
technology systems, or those of the third parties upon whom we rely. A cybersecurity incident or other interruption could disrupt our
ability, and that of third parties upon whom we rely, to provide our products and services and conduct clinical trials.

The costs related to significant
cybersecurity incidents or disruptions could be material and cause us to incur significant expenses. If the information technology systems
of our CROs, clinical sites, and other contractors and consultants become subject to disruptions or cybersecurity incidents, we may have
insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event,
and to develop and implement protections to prevent future events of this nature from occurring.

If any such incidents were
to occur and cause interruptions in our operations, it could result in a disruption of our business and development programs. For example,
the loss of clinical trial data from completed or ongoing clinical trials for a product candidate could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data, or may limit our ability to effectively execute
a product recall, if required in the future. To the extent that any disruption or cybersecurity incident were to result in the loss of
or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur
liability and the further development of any product candidates could be delayed. Applicable data privacy and security obligations may
require us